Patient Condition
Retired engineers will experience a decline in awareness in 2023. The Affiliated Hospital of the University of Tokyo School of Medicine assessed that the MMSE score was 21 points, and early AD was diagnosed, which met the indications for Donanemab treatment.
Treatment Timeline
| Phase | Details | Date |
|---|
| Comprehensive cognitive assessment and biomarker testing | | |
| Donanemab anti-amyloid therapy initiated | | |
| Joint cognitive rehabilitation and functional training | | |
| Maintenance treatment and long-term follow-up | | |
Treatment Outcome
| before | MMSE score 21 points, cognitive decline, difficulty in engineering calculation |
|---|
| after | MMSE score 26 points (improvement by 5 points), cognitive function improved, ability to carry out engineering-related reading |
|---|
| highlight | Improved technical awareness and maintenance of professional interests |
|---|